Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01123876 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01123876 is a Phase 1 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 60 participants.
The verdict
NCT01123876, a Phase 1 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
Assess whether the combination of ABT-888 with FOLFIRI has activity in subjects with gastric cancer.
Interventions
- DRUG Veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01123876
The ClinicalTrials.gov registry entry for NCT01123876 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Veliparib is the first listed.
NCT01123876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01123876 about?
NCT01123876 is a clinical study titled "Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor". Assess whether the combination of ABT-888 with FOLFIRI has activity in subjects with gastric cancer.
What is the current status of trial NCT01123876?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2010-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01123876?
The interventions under investigation include: Veliparib (DRUG).
Who is sponsoring clinical trial NCT01123876?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.